Oxurion Competitors and Similar CompaniesClear all
Alnylam's competitors and similar companies include Catalyst Pharmaceuticals.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. | |
Founding Date | Founding Date 2002 | Founding Date 2002 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Coral Gables, US HQ | |
Employees | Employees 1,32324% increase | Employees 7649% increase |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 2.6 b |
Financial | ||
Revenue (est.) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) $589m (FY, 2025) |
Cost of goods | Cost of goods $677.2m (FY, 2025) | Cost of goods $87.3m (FY, 2025) |
Gross profit | Gross profit $3b (FY, 2025) | Gross profit $501.7m (FY, 2025) |
Net income | Net income $313.7m (FY, 2025) | Net income $214.3m (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
Catalyst Pharmaceuticals
HQ
Coral Gables, US
Employees
76↑ 49% increase
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
View company